Lumida
/SLS
⌘K
Sellas Life Sciences Group Inc

Sellas Life Sciences Group Inc

SLS
$11.55USD-14.42%-1.95 today

MARKET CAP

2.3B

P/E (TTM)

FWD P/E

DAY RANGE

$11 – $14

52W RANGE

$1
$16

AI Summary

Stalk
TrimMedium

A decisive support failure below the 9/20/50 EMAs signals medium-term bearish acceleration despite a still-intact long-term uptrend above the 200 DMA. Oversold conditions warrant caution against chasing the decline, and under a Speculative mandate, the preferred approach is to defer short entry until a pullback into the broken support zone offers a clear rejection setup.

  • Galinpepimut-S (GPS) advancing toward Phase 3 readout with strong early efficacy data
  • $138.3 M cash and equivalents support late-stage trials through 2026
  • Q2 net loss widened to $9.6 M, R&D spend rose to $6.3 M
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2019FY 2020FY 2021FY 2022TREND
Sales, Adj.$0$1.9M$7.6M$1.0M
YoY %+300.0%-86.8%
P / Sales24.4x11.3x49.5x
EV / Sales15.3x9.2x48.4x
Gross Profit, Adj.$0$1.9M$7.4M$900,000
YoY %+289.5%-87.8%
Margin %100.0%97.4%90.0%
EV / Gross Profit15.3x9.5x53.8x
EBITDA, Adj.$-17.2M$-17.0M$-19.6M$-31.9M
YoY %+20.1%+1.3%-15.4%-63.1%
Margin %-893.8%-257.8%-3195.0%
EV / EBITDA-0.8x-1.7x-3.6x-1.5x
EBIT$-20.0M$-17.0M$-25.3M$-42.0M
YoY %+35.5%+15.3%-48.9%-65.8%
Margin %-893.8%-332.8%-4195.0%
EV / EBIT-0.7x-1.7x-2.8x-1.2x
Net Income$-28.0M$-16.8M$-20.7M$-41.3M
YoY %+32.2%+39.8%-23.0%-99.5%
Net Margin-886.1%-272.4%-4130.1%
EPS (GAAP)-$10.92-$2.11-$1.34-$2.13
YoY %+93.1%+80.7%+36.5%-59.0%